NovaBridge Biosciences (NBP) Receivables - Accured (2018 - 2026)
NovaBridge Biosciences (NBP) posted quarterly Receivables - Accured of $5000.0 for Q4 2025, down 99.52% year-over-year from $1.0 million in Q4 2024, and down 83.33% quarter-over-quarter from $30000.0 in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Receivables - Accured (2018 - 2026) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Receivables - Accured for 5 consecutive years, with $5000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Accured fell 99.52% year-over-year to $5000.0; the TTM figure through Dec 2025 stood at $5000.0 (down 99.52% YoY), while the FY2025 annual figure was $5000.0, down 99.52% from the prior year.
- Receivables - Accured eased to $5000.0 in Q4 2025 per NBP's latest filing, from $30000.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $1.0 million in Q4 2024 and bottomed at $5000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2020 | 35,610.82 |
| Dec 31, 2019 | 108,396.91 |
| Dec 31, 2018 | 217,233.64 |